Lifecell kündigt Rekord Umsatz und Gewinn an. (P/E) 1.9 - 500 Beiträge pro Seite

[Kubrick2001]

Lifecell ist eine Tissue Engineering Company aus den USA, welche gemessen am Umsatz noch sehr günstig bewertet ist (KUV 1.9). Grund für die niedrige Bewertung ist meiner Meinung nach die Unsicherheit gewesen ob Lifecell mit seinen luiquiden Mitteln auskommt.
Cash-Reserven noch ca. 5 Millionen Dollar. Mit erreichen der Profitablität dürfte Lifecell eine höhere Bewertung am Markt erreichen.

Üblich für profitable Biotechnologie Firmen P/E min. 10.

Wer sich über Lifcell informieren möchte, hier ein recht umfassender Thread, der sich mit der Firma seit ca. einem halben Jahr beschäftigt.
http://www.wallstreet-online.de/ws/community/board/threadpag…

und hier die Meldung:

Press Release
SOURCE: LifeCell Corporation
LifeCell to Post Record Product Revenues for 2001
BRANCHBURG, N.J., Jan. 17 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC - news), a leader in developing and commercializing biological solutions to repair or replace the body`s damaged tissue, announced today that the Company expects to report record product revenues for the year ended December 31, 2001. LifeCell currently markets three products, AlloDerm® for plastic reconstructive and burn procedures, Cymetra(TM) for the correction of soft tissue defects, and Repliform(TM) for urology and gynecology procedures.

LifeCell`s product portfolio is derived from the Company`s versatile acellular matrix technology platform and is used for the repair, replacement and preservation of tissue in numerous different clinical applications. The Company expects to report 2001 product revenues of approximately $26.6 million, up 25% from the previous year.

``In addition to record product revenues for the year, we expect to report an operating profit in the fourth quarter of 2001, the first ever in the Company`s history,`` said Paul Thomas, President and CEO of LifeCell. ``With several products on the market and consistent double-digit revenue growth, we look forward to an exciting 2002 as we leverage LifeCell`s technology base to enter into larger target markets such as orthopedics and cardiovascular.``

LifeCell`s audited financial results for the twelve-month period ended December 31, 2001, are scheduled to be released on Tuesday, February 26, 2002.

LifeCell Corporation is a leader in developing and marketing solutions for the repair, replacement and preservation of human tissue. The Company`s core technology removes all cells from the tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets three human tissue products: AlloDerm® for plastic reconstructive and burn procedures through LifeCell`s direct sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in particulate form for the correction of soft tissue defects, through LifeCell`s direct sales force and a co-promotion agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific Corporation. The Company`s development programs include the application of its core technology to vascular, nerve and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as our expectation for revenue growth, profitability and product development. Forward-looking statements represent management`s judgment regarding future events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in the Company`s Annual Report on Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission.

SOURCE: LifeCell Corporation

schöne Grüße
Kubrick

[Kubrick2001]

Mir ist ein Fehler passiert. Schreibe in der Überschrift price/earning 1.9, meinte aber price/revenue 1.9.

Sorry Kubrick

[matthiasch]

Lass den Thread löschen, der irritiert sonst..

[matthiasch]

Üblich für profitable Biotechnologie Firmen P/E min. 10.
meintest hier wahrscheinlich auch Price/revenue, oder? Wenn nicht dann wäre deine Aussage ja falsch.



Der von mir herauskopierte Satz gefällt mir überhaupt nicht. Du siehst ja, was momentan mit den Bios geschieht- die bringen die P/R auf das richtige Niveau, und das sollte bei 3 angemessen sein.


Der Satz kommt mir irgendwie bekannt vor: Üblich für Profitable Internet-Firmen P/R von min. 10....

[Kubrick2001]

Du hast recht, es sollte heißen price/revenue min. 10.

"Der von mir herauskopierte Satz gefällt mir überhaupt nicht. Du siehst ja, was momentan mit den Bios geschieht- die bringen die P/R auf das richtige Niveau, und das sollte bei 3 angemessen sein."

Die Aktie von Lifecell hätte auch bei deinem gewählten p/r Verhältnis noch ein Potential von ca. 80%.

Gruß Kubrick